Fjarde AP Fonden Fourth Swedish National Pension Fund Decreases Holdings in Revvity, Inc. (NYSE:RVTY)

Fjarde AP Fonden Fourth Swedish National Pension Fund decreased its holdings in Revvity, Inc. (NYSE:RVTY) by 40.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,740 shares of the company’s stock after selling 13,900 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Revvity were worth $2,315,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the business. Empirical Finance LLC increased its stake in shares of Revvity by 2.0% in the third quarter. Empirical Finance LLC now owns 4,237 shares of the company’s stock worth $541,000 after purchasing an additional 85 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its position in shares of Revvity by 2.4% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 4,214 shares of the company’s stock valued at $470,000 after acquiring an additional 100 shares during the period. HB Wealth Management LLC boosted its position in shares of Revvity by 4.6% in the fourth quarter. HB Wealth Management LLC now owns 2,380 shares of the company’s stock valued at $266,000 after acquiring an additional 104 shares during the period. Westside Investment Management Inc. boosted its position in shares of Revvity by 0.8% in the fourth quarter. Westside Investment Management Inc. now owns 14,363 shares of the company’s stock valued at $1,603,000 after acquiring an additional 108 shares during the period. Finally, Coldstream Capital Management Inc. boosted its position in shares of Revvity by 5.1% in the third quarter. Coldstream Capital Management Inc. now owns 2,247 shares of the company’s stock valued at $286,000 after acquiring an additional 110 shares during the period. Hedge funds and other institutional investors own 86.65% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on RVTY shares. Barclays raised their price objective on shares of Revvity from $135.00 to $140.00 and gave the company an “overweight” rating in a research report on Monday, February 3rd. Robert W. Baird raised their price objective on shares of Revvity from $136.00 to $138.00 and gave the company an “outperform” rating in a research report on Tuesday, November 5th. Sanford C. Bernstein lowered shares of Revvity from an “outperform” rating to a “market perform” rating and set a $130.00 price objective for the company. in a research report on Friday, January 10th. Bank of America upgraded shares of Revvity from a “neutral” rating to a “buy” rating and set a $138.00 target price for the company in a research report on Friday, December 13th. Finally, TD Cowen lifted their target price on shares of Revvity from $141.00 to $144.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. Four investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Revvity presently has a consensus rating of “Moderate Buy” and an average price target of $136.25.

Insider Buying and Selling at Revvity

In other news, insider Joel S. Goldberg sold 15,170 shares of the business’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $126.73, for a total transaction of $1,922,494.10. Following the sale, the insider now owns 33,400 shares in the company, valued at approximately $4,232,782. The trade was a 31.23 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Tajinder S. Vohra sold 5,492 shares of the business’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $116.81, for a total transaction of $641,520.52. Following the sale, the insider now owns 19,652 shares in the company, valued at approximately $2,295,550.12. This trade represents a 21.84 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.60% of the company’s stock.

Revvity Stock Down 0.4 %

Shares of NYSE RVTY opened at $115.00 on Thursday. The company has a quick ratio of 3.03, a current ratio of 3.60 and a debt-to-equity ratio of 0.41. Revvity, Inc. has a 52 week low of $97.32 and a 52 week high of $129.50. The firm’s fifty day moving average is $116.89 and its 200 day moving average is $118.57. The company has a market cap of $14.00 billion, a price-to-earnings ratio of 52.04, a PEG ratio of 3.82 and a beta of 1.03.

Revvity (NYSE:RVTY) last issued its earnings results on Friday, January 31st. The company reported $1.42 EPS for the quarter, topping the consensus estimate of $1.37 by $0.05. Revvity had a net margin of 9.81% and a return on equity of 7.68%. During the same period in the prior year, the business earned $1.25 EPS. On average, equities research analysts expect that Revvity, Inc. will post 4.94 earnings per share for the current year.

Revvity Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 9th. Shareholders of record on Friday, April 18th will be given a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a yield of 0.24%. The ex-dividend date of this dividend is Thursday, April 17th. Revvity’s payout ratio is currently 12.67%.

Revvity declared that its Board of Directors has initiated a share buyback program on Monday, November 4th that permits the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization permits the company to buy up to 6.5% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s board of directors believes its stock is undervalued.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.